Reviva Pharmaceuticals (RVPH) Proxy Filing summary

Voting matters and shareholder proposals

• Proposal 5 concerns a Reverse Stock Split, with updated disclosure correcting previously understated figures for authorized but unissued and unreserved shares after the split.

• The Reverse Split is proposed at ratios ranging from 1:2 to 1:20, with detailed projections for each scenario.

• If the Increase in Authorized Proposal passes, authorized shares of common stock will rise from 315,000,000 to 515,000,000.

Shareholder rights and capital structure

• The Reverse Split will reduce the number of shares each stockholder owns but will not affect their proportional voting rights or other preferences, except for fractional shares.

• The number of stockholders of record will remain unchanged after the Reverse Split.

• The Reverse Split will not impact the number of shares authorized under the Certificate of Incorporation unless the Increase in Authorized Proposal is approved.

• If approved, the number of authorized but unissued and unreserved shares will significantly increase post-split.

Trading performance and revenue trends

• Estimated post-split trading prices are provided for each split ratio, based on the October 21, 2025 closing price.

• The common stock will continue to be listed on Nasdaq, with a temporary symbol change to indicate the split.